BillionToOne Inc

BLLN

Market cap $5.5B

Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so far this year.

Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts MENLO PARK, Calif., June 29, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the publication of Longitudinal Methylated ctDNA Increases Predict Immunotherapy Progression Across Solid Tumors , a peer-reviewed study demonstrating that Northstar Response® was a stronger predictor of survival than standard-of-care imaging in patients with advanced solid tumors receiving immunotherapy or immunotherapy combination therapy, and that the addition of molecular monitoring to imaging provided greater predictive power than imaging alone.

Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the William Blair 46th Annual Growth Stock Conference.

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

The average of price targets set by Wall Street analysts indicates a potential upside of 37% in BillionToOne (BLLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BillionToOne delivered 84% YoY Q1 sales growth, driven by prenatal and oncology clinical testing segments. BillionToOne raised full-year revenue guidance to $450–$465 million, reflecting strong demand, pricing, and volume momentum. GAAP operating profit reached $17.8 million, demonstrating operating leverage and margin expansion amid declining pricing pressure.

The mean of analysts' price targets for BillionToOne (BLLN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026.